Morice, A., et al. (2025). FGFR antagonists restore defective mandibular bone repair in a mouse model of osteochondrodysplasia. Bone Research. doi.org/10.1038/s41413-024-00385-x.

A new study explores the potential of fibroblast growth factor receptor (FGFR) antagonists in restoring defective mandibular bone repair in mouse models of osteochondrodysplasia, a group of ...

In their review, the authors describe the FGFR pathway, its role in oncogenesis, current FGFR inhibitors, the role these inhibitors play in treatment cholangiocarcinoma, and the future of the field.

Drugs targeting FGFR mutations, which are seen in patients with intrahepatic cholangiocarcinoma (CCA), have generated particular excitement; the authors note that prior to the approval of ...

The significance of FGFR as an important oncogenic driver in multiple cancers is evident in the expanding array of approved FGFR inhibitors, including futibatinib and pemigatinib in cholangiocarcinoma ...

Meeting Coverage > ASCO FGFR Inhibitor Stakes Claim to Post-Anti-PD-1 Role in Advanced Bladder Cancer — Survival benefit supports FGFR testing for all patients with metastatic disease ...

We identified 41 patients with tumors harboring an oncogenic FGFR alteration. Median age at diagnosis was 8 years (range, 6 months-26 years). Diagnoses included 11 rhabdomyosarcomas, nine low-grade ...

Among the 12 patients with FGF/FGFR gene aberrations who have completed at least one tumor assessment, the overall response rate (ORR) was 33.3%, including 1 patient (8.3%) of cholangiocarcinoma ...

Futibatinib demonstrated clinical benefit among previously treated patients with fibroblast growth factor receptor 2 fusion- or rearrangement-positive intrahepatic cholangiocarcinoma, according to ...

Correspondence Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia Published September 9, 2020 N Engl J Med 2020;383: 1387 - 1389 DOI: 10.1056/NEJMc2020399 ...